Nykode

Joint Global Coordinator & Joint Lead Bookrunner

Van Lanschot Kempen acted as Joint Global Coordinator and Joint Lead Bookrunner in Nykode’s NOK 505 million Capital Increase.

Transaction Highlights

Capital increase raising NOK 505 million (c. EUR 43 million) via a placement of 29.6 million new shares, representing a 10% increase
The order book was multiple times oversubscribed and saw significant demand from new international investors, demonstrated by the largest existing shareholders not being allocated any shares in the offering, while initially having pre-committed up to NOK 330 million
Nykode, the largest Norwegian biotech company by market cap, intends to use the proceeds to advance its lead cancer immunotherapy VB10.16, pipeline and proprietary Vaccibody technology platform
This transaction represents Van Lanschot Kempen’s fourth ECM transaction for a Nordic Life Sciences company in 2023, underpinning the ability of Van Lanschot Kempen to support companies in the Nordic

Van Lanschot Kempen Life Sciences & Healthcare credentials

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

Sole Financial Adviser in the SEK 120 million Structured Equity transaction by Synact Pharma
Lead Manager in the USD 173 million Capital Increase by Merus
Manager in the USD 1.3 billion Capital Increase by argenx
Joint Bookrunner in the SEK 500 million Capital Increase by Vicore Pharma
Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors
Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics
Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
Lead Manager in the USD 250 million Capital Increase by CureVac
Sole Financial Adviser to GenSight Biologics in securing a EUR 12 million credit facility from Heights Capital Management
Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
Joint Bookrunner in the SEK 200 million Capital Increase by Vicore Pharma
Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
Financial Adviser to GenSight Biologics in securing a EUR 35 million credit facility from the European Investment Bank
Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Capital Increase by Xbrane Biopharma
Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma

Company Description

Nykode is a Norwegian clinical-stage biopharmaceutical company developing cancer immunotherapies based on its proprietary Vaccibody vaccination technology. Nykode's lead asset, VB10.16, is a therapeutic vaccine against HPV16+ cancers and is currently in Phase II development for cervical cancer and HNSCC. The Company has high profile R&D collaborations with Roche/Genentech, Regeneron and Adaptive Biotechnologies

Contact

Jan de Kerpel

Mail Jan de Kerpel

Pieter van der Meijden

Mail Pieter van der Meijden